Allogeneic hematopoietic transplantation for mantle-cell lymphoma: Molecular remissions and evidence of graft-versus-malignancy

Annals of Oncology

Volumn 10, Issue 11, 1999, Pages 1293-1299

  Khouri, I F ^a   Lee, M S ^a   Romaguera, J ^a   Mirza, N ^a   Kantarjian, H ^a   Korbling, M ^a   Albitar, M ^a   Giralt, S ^a   Samuels, B ^a   Anderlini, P ^a   Rodriguez, J ^a   Von Wolff, B ^a   Gajewski, J ^a   Cabanillas, F ^a   Champlin, R ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Allogeneic transplantation for mantle cell lymphoma

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; METHOTREXATE; VINCRISTINE;

ALLOGRAFT; ARTICLE; CANCER REGRESSION; CANCER STAGING; CLINICAL ARTICLE; DRUG MEGADOSE; DRUG RESPONSE; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MANTLE CELL LYMPHOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

EID: 0032778810     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008380527502     Document Type: Article

References (42)

1. Weisenberger DD, Armitage JO. Mantle cell lymphoma - an entity comes of age. Blood 1996; 87: 4483-94.
2. Shivdasani RA, Hess JL, Skarin Atm et al. Intermediate lymphocytic lymphoma: Clinical and pathologic features of a recently characterized subtype of non-Hodgkin's lymphoma. J Clin Oncol 1993; 11: 802-11.
3. Pittaluga S, Bijnens L, Teodorovic I et al. Clinical analysis of 670 cases in two trials of the European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Group subtyped according to the Revised European-American Classification of lymphoid neoplasms: A comparison with the working formulation. Blood 1996; 87: 4358-67.
4. Majlis A, Pugh W, Rodriguez M et al. Mantle-cell lymphoma: Correlation of clinical outcome and biologic features with three histologic variants. J Clin Oncol 1997; 15: 1664-71.
5. Khouri IF, Romaguera J, Kantarjian H et al. Hyper-CVAD and high-dose methotrexate-cytarabine followed by stem-cell transplantation: An active regimen for aggressive mantle-cell lymphoma. J Clin Oncol 1998; 16: 3803-9.
6. Freedman AS, Neuberg D, Gribben JG et al. High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: No evidence for long-term remission. J Clin Oncol 1998; 16: 13-8.
7. Khouri IF, Przepiorka D, van Besien K et al. Allogeneic blood or marrow transplantation for chronic lymphocytic leukemia: Timing of transplantation and potential effect of fludarabine on acute graft-versus-host disease. Br J Haematol 1997; 97: 466-73.
8. Van Besien KW, Khouri IF et al. Allogeneic bone marrow transplantation for refractory and recurrent low-grade lymphoma. The case for aggressive management. J Clin Oncol 1995; 13: 1096-102.
9. Verdonck LF, Dekker AW, Lokhorst HM et al. Allogeneic versus autologous bone marrow transplantation for refractory and recurrent low-grade non-Hodgkin's lymphoma. Blood 1997; 90: 4201-5.
10. Van Besien K, Sobocinski KA, Rowlings PA et al. Allogeneic bone marrow transplantation for low-grade lymphoma. Blood 1998; 92: 1832-6.
11. Applebaum FR, Sullivan KM, Buckner CD et al. Treatment of malignant lymphoma in 100 patients with chemotherapy, total body irradiation, and marrow transplantation. J Clin Oncol 1987; 5: 1340-7.
12. Lundberg JH, Hansen RM, Chitambar CR et al. Allogeneic bone marrow transplantation for relapsed and refractory lymphoma using genotypically HLA-identical and alternative donors. J Clin Oncol 1991; 9: 1848-59.
13. Jones RJ, Armbinder RF, Piantadosi S et al. Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation. Blood 1991; 77: 649-53.
14. Chopra R, Goldstone AH, Pearce R et al. Autologous versus allogeneic bone marrow transplantation for non-Hodgkin's lymphoma: A case-controlled analysis of the European Bone Marrow Transplantation Group Registry Data. J Clin Oncol 1992; 10: 1690-5.
15. Shepherd JD, Barnett MJ, Connors JM et al. Allogeneic bone marrow transplantation for poor-prognosis non-Hodgkin's lymphoma. BMT 1993; 12: 591-6.
16. Ratanatharathorn V, Uberti J, Karanes C et al. Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin's lymphoma. Blood 1994; 84: 1050-5.
17. Van Besien KW, Mehra RC, Giralt SA et al. Allogeneic bone marrow transplantation for poor-prognosis lymphoma: Response, loxicity, and survival depend on disease histology. Am J Med 1996; 100: 299-307.
18. Juckett M, Rowlings P, Hessner M et al. T-cell-depleted allogeneic bone marrow transplantation for high-risk non-Hodgkin's lymphoma: Clinical and molecular follow-up. BMT 1998; 21: 893-9.
19. Dann EJ, Daugherty CK, Larson RA. Allogeneic bone marrow transplantation for relapsed and refractory Hodgkin's disease and non-Hodgkin's lymphoma. BMT 1997; 20: 369-74.
20. Mandigers CMPW, Raemaekers JMM, Schattenberg AVMB et al. Allogeneic bone marrow transplantation with T-cell-depleted marrow grafts for patients with poor-risk relapsed low-grade non-Hodgkin's lymphoma. Br J Haematol 1998; 100: 198-206.
21. Van Besien KW, De Lima M, Giralt S et al. Management of lymphoma recurrence after allogeneic transplantation: The relevance of graft-versus-lymphoma effect. BMT 1997; 19: 977-82.
22. Rondon G, Giralt S, Huh Y et al. Graft-versus-leukemia after allogeneic bone marrow transplantation for chronic lymphocytic leukemia. BMT 1996; 18: 669-72.
23. Khouri IF, Keating M, Korbling M et al. Transplant-lite: Induction of graft-versus-malignancy using fludarabine based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 1998; 16: 2817-24.
24. Przepiorka D, Anderlini P, Ippoliti C et al. Allogeneic blood stem-cell transplantation in advanced hematologic cancers. BMT 1997; 19: 455-60.
25. Przepiorka D, Ippoliti C, Khouri I et al. Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after matched unrelated donor marrow transplantation. Blood 1996; 88: 4383-9.
26. Yam P, Petz LD, Ali S, Stock AD, Wallace RB. Development of a single probe for documentation of chimerism following bone marrow transplantation. Am J Hum Genet 1987; 41: 867-81.
27. Bearman SI, Appelbaum FR, Buckner CD et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 1998; 6: 1562-8.
28. Przepiorka D, Weisdorf D, Martin P et al. Consensus conference on acute GVHD grading. BMT 1995; 15: 825-8.
29. Tsujimoto Y, Yunis J, Onorato-Showe L et al. Molecular cloning of the chromosomal breakpoint of B-cell lymphomas and leukemias with the t(11;14) chromosome translocation. Science 1984; 224: 1403-7.
30. Williams ME, Swerdlow SH, Meecker TC. Chromosome t(11;14)(q13;q32) breakpoints in centrocytic lymphoma are highly localized at the bcl-1 major translocation cluster. Leukemia 1993; 7: 1437-40.
31. Rimokh R, Berger F, Delsol G et al. Detection of the chromosomal translocation t(11;14) by polymerase chain reaction in mantle-cell lymphomas. Blood 1994; 83: 1871-5.
32. Yamada M, Hudson SA, Tournay O et al. Detection of minimal residual disease in hematopoietic malignancies of the B-cell lineage by using third-complementary-determining region (CDR-III)-specific probes. Proc Natl Acad Sci USA 1989; 86: 5122-7.
33. Ravetech JV, Siebenlist U, Korsmeyer W et al. Structure of the human immunoglobulin F locus: Characterization of embryonic and rearranged J and D genes. Cell 1981; 27: 583-91.
34. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-81.
35. Horowitz MM, Gale RP, Sondel PM et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555-62.
36. Kolb HJ, Mittermuller J, Clemm Ch et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990; 76: 2462-9.
37. Kolb HJ, Schattenberg A, Goldman JM et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995; 86: 2041-50.
38. Falkenburg JHF, Goselink HM, van der Harst D et al. Growth inhibition of clonogenic leukemic precursor cells by minor histocompatibility antigen-specific cytotoxic T lymphocytes. J Exp Med 1991; 174: 27-33.
39. Champlin RE Separation of graft-versus-host disease and graft-versus-leukemia against chronic myelogenous leukemia. Exp Hematol 1995; 23: 1148-51.
40. Giralt S, Estey E. Albitar M et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog containing chemotherapy: Harnessing graft-versus-leukemia without myelo-ablative therapy. Blood 1997; 89: 4531-6.
41. Storb R, Yu C, Wagner JL et al. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood 1997; 89: 3048-54.
42. Slavin S, Nagler A, Naparstek E et al. Nonmyeloablative stem-cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756-63.